BioReliance Launches Global Sales and Marketing Organization

Diana Morgan, Ph.D. Named Vice President of the Worldwide Group

Oct 02, 2003, 01:00 ET from BioReliance Corporation

    ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- BioReliance Corporation
 (Nasdaq:   BREL) announced today that it has launched a global sales and
 marketing organization, now offering its biologics testing and manufacturing
 services on a comprehensive basis to clients around the world.  This
 reorganization follows BioReliance's acquisition of Q-One Biotech,
 headquartered in Glasgow, Scotland, and represents a major step in
 implementing the Company's post-acquisition strategy of serving its
 international client base with global service offerings and support.  The move
 integrates a sales and marketing function that had been segmented regionally.
     As a newly appointed vice president, Diana Morgan, Ph.D., 50, will now
 lead the global sales and marketing organization from her offices in Glasgow,
 Scotland and Rockville, Maryland.  Dr. Morgan most recently had been the
 Director of Sales for European Testing, Development and Manufacturing for
 BioReliance.  She joined the Company in 1994 following a successful career
 spanning 14 years at The Beatson Institute for Cancer Research, where she
 gained her doctorate, followed by a number of years as Laboratory Manager at
 the Leukemia Research Fund Laboratory established by Professor David Onions,
 one of the founders of Q-One Biotech.  Key personnel from both the former
 Q-One and BioReliance organizations join her team in this integration.
     Capers W. McDonald, President and CEO, said, "This reorganization is part
 of creating a more capable and global service enterprise.  We are delighted
 that Dr. Morgan will be leading us beyond the additive combination of our two
 organizations to better serve the global marketplace.  With approximately half
 of our business now originating outside North America, we are fortunate to
 have someone of Dr. Morgan's international experience in this newly created
 position.  We therefore view the initial costs of globalization -- relating
 both to the acquisition of Q-One and the reorganization of our sales and
 marketing -- as important investments that position us to provide a new level
 of service in our competitive marketplace."
     In accepting her new role, Dr. Morgan commented, "This opportunity is of
 tremendous value to our current and prospective clients.  Q-One has been an
 outstanding service provider, and they are already complementing our growing
 U.S. and U.K. operations.
     "Quality, science and services that can be relied upon worldwide are key
 parts of our strategy and a continuing pledge to our clients going forward.
 These capabilities are continuing at all sites -- in Glasgow and Stirling in
 the U.K., in Worcester and Rockville in the U.S., and in Heidelberg in
     Dr. Morgan continued, "The combination of BioReliance and Q-One has
 created an expanded, more vital service company.  We now provide extended
 resources and know-how to serve the needs of our customers.  We are increasing
 our range of services, since we plan the continued availability of Q-One
 assays.  We enjoy considerably greater capacities for scheduling client work,
 enhancing timeliness while maintaining quality.  We will continue both custom
 and standard services, and can better source required services in the most
 cost effective manner possible.  The combination also will enhance multi-site
 backup capabilities for many services."
     The Company also announced that Ronald Baker, former Vice President of
 Sales and Marketing in the U.S., has left the Company to pursue other
     About BioReliance
     BioReliance Corporation is a leading, global contract service organization
 providing integrated testing, development and manufacturing services for
 biologics and other biomedical products to biotechnology and pharmaceutical
 companies worldwide.  The Company believes it is the largest provider of
 outsourcing services focused on the expanding biologics sector of the
 pharmaceutical industry.
     Forward-Looking Statements
     Certain statements made in this release are "forward-looking statements"
 within the meaning of the Private Securities Litigation Reform Act of 1995.
 Forward-looking statements include, without limitation, any statement that may
 predict, forecast, indicate, or imply future results, performance, or
 achievements, and may contain the words "believe," "anticipate," "confident,"
 "expect," "estimate," "project," "will be," "will continue," "will likely
 result," or similar words or phrases.  Comments such as those with respect to
 BioReliance's ability to integrate effectively and efficiently the operations
 of Q-One Biotech, constitute forward-looking statements.  As and when made,
 management believes that these forward-looking statements are reasonable.
 BioReliance undertakes no obligation to revise or publicly release the results
 of any revision to these forward-looking statements.  Forward-looking
 statements involve risks and uncertainties, which may cause actual results to
 differ materially from the forward-looking statements.  Risks and
 uncertainties are detailed from time to time in reports filed by BioReliance
 with the Securities and Exchange Commission, including in its Forms 10-K and
 10-Q.  Given these risks and uncertainties, investors should not place undue
 reliance on forward-looking statements as a prediction of actual results.

SOURCE BioReliance Corporation